This file illustration dated to Dec 19, 2022 shows the Neuralink logo and an Elon Musk photo. (ILLUSTRATION / REUTERS)
LOS ANGELES – Neuralink, Elon Musk's brain-machine interface company, announced Thursday it has received approval from the US Food and Drug Administration (FDA) to conduct its first-in-human clinical study.
"This is the result of incredible work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our technology to help many people," the company tweeted.
Neuralink said recruitment for its clinical trial "is not open yet."
READ MORE: Animal tests: Musk faces federal probe, employee backlash
The FDA has not commented on the trial. And the extent of the approved trial is not known yet.
This video grab made from the online Neuralink livestream shows the Neuralink disk implant held by Elon Musk during the presentation on Aug 28, 2020. (PHOTO / NEURALINK VIA AFP)
Neuralink was founded in 2016 and funded primarily by Musk to develop a new kind of interface technology between the human brain and computing devices.
ALSO READ: Future of high-tech may rely more on brain power
Installing a chip in the human skull could restore limb function, improve human movement, resolve issues with eyesight and hearing, and help with diseases like Parkinson's, the company claims.